Japanese Vaccine Maker Biken To Invest ¥35 Billion To Establish New Flu Vaccine Facility
This article was originally published in PharmAsia News
Executive Summary
The Research Foundation for Microbial Disease of Osaka University (Biken) will establish a new vaccine production facility in Kagawa Prefecture. Biken plans to invest ¥35 billion to build the research and manufacturing complex in a 160,000 square foot area. To be completed in 2013, the facility will be able to manufacture flu vaccines for half of Japan's population (60 million) in six months. Biken uses dog kidney cells to culture virus, which cuts the current one year production time in half. (Click here for more - Japanese language)
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.